Mar 25, 2009 - Allos Therapeutics, Inc. today announced that it has submitted a New Drug Application (NDA) to the U.S. FDA for the use of pralatrexate for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). The Company has requested a priority review of the application, which, if granted, would give the FDA six months from receipt of the submission to take action on the application.
The details can be read here.
No comments:
Post a Comment